A randomized trial of cefepime (BMY-28142) and ceftazidime for the treatment of pneumonia.

@article{Edelstein1991ART,
  title={A randomized trial of cefepime (BMY-28142) and ceftazidime for the treatment of pneumonia.},
  author={H E Edelstein and Valerie A. Chirurgi and Sharon E. Oster and Richard Alan Karp and Karen Cassano and Stuart Aiken and Robert E. Mccabe},
  journal={The Journal of antimicrobial chemotherapy},
  year={1991},
  volume={28 4},
  pages={
          569-75
        }
}
Cefepime is a new cephalosporin with a broad antimicrobial spectrum that includes Staphylococcus aureus and Pseudomonas aeruginosa. To study the efficacy and safety of cefepime for treatment of pneumonia, 65 patients were randomized to therapy with either cefepime or ceftazidime at a two to one ratio. Of the 57 evaluable patients, 89% of the cefepime patients and 84% of the ceftazidime patients were cured clinically or improved. Haemophilus spp., Streptococcus pneumoniae, and Neisseria spp… CONTINUE READING

Topics from this paper.